Analysis of early hypertension and clinical outcome with bevacizumab: Results from seven phase III studies

Oncologist

Volumn 18, Issue 3, 2013, Pages 273-280

  Hurwitz, Herbert I ^a   Douglas, Pamela S ^b   Middleton, John P ^b   Sledge, George W ^c   Johnson, David H ^d   Reardon, David A ^b   Chen, Dafeng ^e   Rosen, Oliver ^e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e GENENTECH INC   (United States)

Author keywords

Bevacizumab; Clinical outcome; Hypertension; Predictive factor; Prognostic factor

Indexed keywords

ALPHA2A INTERFERON; ANTHRACYCLINE ANTIBIOTIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BREAST METASTASIS; COLORECTAL CANCER; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; HYPERTENSION; KIDNEY NEOPLASMS; LUNG NEOPLASMS; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84875409996     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0339     Document Type: Article

References (34)

1. AVASTIN package insert (July 2009). South San Francisco, CA: Genentech, 2009.
2. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
3. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-4729.
4. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013-2019.
5. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-2111.
6. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009;27:1227-1234.
7. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13:1253-1259.
8. Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23: 8033-8040.
9. Facemire CS, Nixon AB, Griffiths R et al. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009;54:652-658.
10. Hurwitz HI, Dowlati A, Saini S et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-4227.
11. Holden SN, Eckhardt SG, Basser R et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-1397.
12. Robert NJ, Diéras V, Glaspy J et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-1260.
13. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28: 3239-3247.
14. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-2237.
15. Powers BJ, Olsen MK, Smith VA et al. Measuring blood pressure for decision making and quality reporting: Where and how many measures? Ann Intern Med 2011;154:781-788.
16. Appel LJ, Miller ER 3rd, Charleston J. Improving the measurement of blood pressure: Is it time for regulated standards? Ann Intern Med 2011;154: 838-840.
17. Pickering TG, Hall JE, Appel LJ et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005;45:142-161.
18. Staessen JA, Bieniaszewski L, O'Brien E et al. Nocturnal blood pressure fall on ambulatory monitoring in a large international database. Hypertension 1997;29:30-39.
19. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560-2572.
20. Staessen JA, Wang J, Bianchi G et al. Essential hypertension. Lancet 2003;361:1629-1641.
21. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536.
22. Delles C, McBride MW, Graham D et al. Genetics of hypertension: From experimental animals to humans. Biochim Biophys Acta 2010;1802:1299-1308.
23. Levy D, Ehret GB, Rice K et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009;41:677-687.
24. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678.
25. Dahlberg SE, Sandler AB, Brahmer JR et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010;28:949-954.
26. Scartozzi M, Galizia E, Chiorrini S et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227-230.
27. Jain L, Sissung TM, Danesi R et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010 Jul 14,29:95.
28. Osterlund P, Soveri LM, Isoniemi H et al. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 2011;104:599-604.
29. De Stefano A, Carlomagno C, Pepe S et al. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 2011;68: 1207-1213.
30. Bono P, Elfving H, Utriainen T et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009;20:393-394.
31. Harzstark AL, Halabi S, Stadler WM et al. Hypertension is associated with clinical outcome for patients (pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206. Paper presented at: Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA.
32. Izzedine H, Ederhy S, Goldwasser F et al. Management of hypertension in angiogenesis inhibitortreated patients. Ann Oncol 2009;20:807-815.
33. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102:596-604.
34. Ryanne Wu R, Lindenberg PA, Slack R et al. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer 2009;40:101-108.